$PGNX News

Last published 6y ago

6y agoLNTH PGNXLantheus Completes Merger with ProgenicsBusiness WireNORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. ...
6y agoPGNXProgenics Stockholders Approve Merger with LantheusGlobeNewswireNEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find,...
6y agoLNTH PGNXLantheus Stockholders Approve Share Issuance For Merger with ProgenicsBusiness WireNORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced that at a special meeting held earlier today, Lantheus’ stockholders voted to approve the issuance of common stock rel ...
6y agoPGNXProgenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific ProgramGlobeNewswire- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% -- 63.9% Change in Disease Management Plan Based on PyL Imaging Results -- Planned NDA Submission On Track for Early Third Quarter...
6y agoPGNXProgenics Pharmaceuticals' (PGNX) CEO David Mims on Q1 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoPGNXProgenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business UpdateGlobeNewswirePending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radiopharmaceutical Therapeutics...
6y agoPGNXProgenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7GlobeNewswireNEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow...
6y agoLNTH PGNXVelan Capital Agrees to Support Merger of Lantheus and ProgenicsBusiness WireNORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines an ...
6y agoLNTH PGNXLantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed MergerBusiness WireNORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificia ...
6y agoPGNXPROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTSGlobeNewswireNEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. “The recent positive top...
6y agoLNTH PGNXLantheus and Progenics Agree to Amended Transaction TermsBusiness WireNORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines an ...
6y agoPGNXProgenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic ReviewGlobeNewswireNEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial...
6y agoPGNXProgenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter MeetingGlobeNewswireNEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
6y agoPGNXProgenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary EndpointGlobeNewswire- Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance- Company Expects to Submit an NDA to the FDA in the Second Half of 2020- Conference...
6y agoPGNXProgenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rdGlobeNewswireNEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
6y agoPGNXProgenics Pharmaceuticals Appoints David Mims as Interim Chief Executive OfficerGlobeNewswireNEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
7y agoPGNXProgenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of ElectionsGlobeNewswireNEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...
7y agoPGNXVelan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics BoardBusiness WireALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced it has delivered written consents from the holders of more th ...
7y agoPGNXProgenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial ResultsGlobeNewswireLantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical TherapeuticsAZEDRA...
7y agoPGNXProgenics Reminds Shareholders that November 17 is the True Deadline for Velan’s Consent SolicitationGlobeNewswireWarns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan Urges Shareholders to Review the S-4 Filing that Will be Made the Week of November 11 about the Value Maximizing Lantheus...
7y agoPGNXGlass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics BoardBusiness WireALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that a leading proxy advisory firm, Glass, Lewis & Co. (“Glas ...
7y agoPGNXProgenics Reminds Shareholders that November 17 is the Only Deadline for Velan’s Consent SolicitationGlobeNewswireNotifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier Dates to Deliver Consents...
7y agoPGNX LNTHProgenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of DirectorsGlobeNewswireISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of...
7y agoPGNXISS Recommends Shareholders Vote on the GREEN Consent Card for Election of Velan Nominees and Removal of Progenics CEOBusiness WireALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that a leading proxy advisory firm, Institutional Shareholder ...
7y agoPGNX AAAPIndependent Director Candidates Nominated by Velan Issue Letter to Progenics ShareholdersBusiness WireALPHARETTA, Ga.--(BUSINESS WIRE)--Today, Dr. Gérard Ber released an open letter to stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX) on behalf of himself and the four other fully-independent director candidates – Dr. Eric J. Ende, Ann MacDougall, Heinz Mäusli and David W. Mims – nominated by Velan Capital, L.P. (“Velan”) for election to the Progenics Boar ...
7y agoPGNXVelan Responds to Misleading Communications from ProgenicsBusiness WireALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today responded to the Company’s presentation and press release, including mi ...
7y agoPGNX LNTHProgenics Highlights Additional Serious Concerns About Velan Capital, L.P.GlobeNewswireFlags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan’s Questionable Securities Trading, Governance and Ethical Practices Asks...
7y agoPGNXProgenics Sends Letter to ShareholdersGlobeNewswireCalls Out Velan’s Pattern of Disregard for Good Corporate Governance and Business Ethics Reminds Shareholders to Sign and Return Progenics’ WHITE Consent Revocation Card NEW YORK, Oct. 21, 2019 ...
7y agoPGNXVelan Issues Presentation Outlining Nominees’ Comprehensive Strategic Plan to Save ProgenicsBusiness WireALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today released a detailed presentation on Progenics. The presentation outline ...
7y agoPGNXProgenics Sends Letter to ShareholdersGlobeNewswireHighlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium...
7y agoLNTH PGNXLantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics CompanyBusiness WireNORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines an ...
7y agoPGNXVelan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director NomineesBusiness WireALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that it has filed a preliminary consent statement with the SEC ...
7y agoPGNXCourt Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® TabletsPR NewswireBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (NASDAQ: PGNX), announced today that...
8y agoPGNXProgenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoPGNXProgenics Pharmaceuticals' (PGNX) CEO Mark Baker on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts